Literature DB >> 12606560

Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.

Natalia V Gorlatova1, Hassan Elokdah, Kristi Fan, David L Crandall, Daniel A Lawrence.   

Abstract

The mechanism for the conversion of plasminogen activator inhibitor-1 (PAI-1) from the active to the latent conformation is not well understood. Recently, a monoclonal antibody, 33B8, was described that rapidly converts PAI-1 to the latent conformation (Verhamme, I., Kvassman, J. O., Day, D., Debrock, S., Vleugels, N., Declerck, P. J., and Shore, J. D. (1999) J. Biol. Chem. 274, 17511-17517). In an attempt to understand this interaction, and more broadly to understand the mechanism of the natural transition of PAI-1 to the latent conformation, we have used random mutagenesis to identify the 33B8 epitope in PAI-1. This site involves at least 8 amino acids scattered over more than two-thirds of the linear sequence that form a compact epitope on the PAI-1 three-dimensional structure. Surface plasmon resonance studies indicate a high affinity interaction between latent PAI-1 and 33B8 that is approximately 100-fold higher than comparable binding to active PAI-1. Structural modeling results together with surface plasmon resonance analysis of parental and site-directed PAI-1 mutants with disrupted 33B8 binding suggest the existence of a specific PAI-1 intermediate structure that is stabilized by 33B8 binding. These analyses strongly suggest that this intermediate form of PAI-1 has a partial insertion of the reactive center loop into beta-sheet A, and together, these data have significant implications for the general serpin mechanism of proteinase inhibition.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12606560     DOI: 10.1074/jbc.M208420200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Serpin latency transition at atomic resolution.

Authors:  Giorgia Cazzolli; Fang Wang; Silvio a Beccara; Anne Gershenson; Pietro Faccioli; Patrick L Wintrode
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

2.  Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability.

Authors:  Jan K Jensen; Lawrence C Thompson; Joel C Bucci; Poul Nissen; Peter G W Gettins; Cynthia B Peterson; Peter A Andreasen; J Preben Morth
Journal:  J Biol Chem       Date:  2011-06-21       Impact factor: 5.157

3.  Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Ashley A Reinke; Karen L Sanders; Cory D Emal; James C Whisstock; Jeanne A Stuckey; Daniel A Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

4.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

5.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

6.  Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.

Authors:  Christine R Schar; Jan K Jensen; Anni Christensen; Grant E Blouse; Peter A Andreasen; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2008-07-24       Impact factor: 5.157

7.  High-affinity binding of plasminogen-activator inhibitor 1 complexes to LDL receptor-related protein 1 requires lysines 80, 88, and 207.

Authors:  Mary Migliorini; Shih-Hon Li; Anqi Zhou; Cory D Emal; Daniel A Lawrence; Dudley K Strickland
Journal:  J Biol Chem       Date:  2019-12-02       Impact factor: 5.157

8.  Characterization of the Annonaceous acetogenin, annonacinone, a natural product inhibitor of plasminogen activator inhibitor-1.

Authors:  Stéphane Pautus; Mouad Alami; Fréderic Adam; Guillaume Bernadat; Daniel A Lawrence; Allan De Carvalho; Gilles Ferry; Alain Rupin; Abdallah Hamze; Pierre Champy; Natacha Bonneau; Philippe Gloanec; Jean-Louis Peglion; Jean-Daniel Brion; Elsa P Bianchini; Delphine Borgel
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

9.  Discovery and characterisation of an antibody that selectively modulates the inhibitory activity of plasminogen activator inhibitor-1.

Authors:  Katherine A Vousden; Tomas Lundqvist; Bojana Popovic; Brian Naiman; Alan M Carruthers; Philip Newton; Daniel J D Johnson; Anja Pomowski; Trevor Wilkinson; Patrick Dufner; Isabelle de Mendez; Philip R Mallinder; Clare Murray; Martin Strain; Jane Connor; Lynne A Murray; Matthew A Sleeman; David C Lowe; James A Huntington; Tristan J Vaughan
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

Review 10.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.